



PRESS RELEASE | ECULLY, FRANCE – 14<sup>th</sup> of June 2020

## **Professor Patrick Couvreur joins the Scientific Council of Seqens led by Professor Bernard Meunier, Former President of the French Académie des Sciences.**

Professor Patrick Couvreur, Emeritus Professor of Pharmacy at Paris-Saclay University, has a world-renowned expertise in the design of new nanomedicines for the treatment of severe diseases in oncology, neurosciences and intracellular resistant infections.

Professor Couvreur joins the Scientific Committee of Seqens to accelerate the Group innovation projects and support Seqens ambition to strengthen its portfolio of ingredients and services in the field of Drug delivery materials, such as Polymers and Lipids, which improve the Bioavailability of Active Pharmaceutical Ingredients (APIs).

Seqens Group offers a range of proprietary Drug Delivery vectors, as well as custom-made synthesis services, to deliver its customers with solutions to improve the formulation of APIs from early-stage development to commercial production, serving all major therapeutic areas, primarily oncology.

As recalled by Bernard Meunier, Former President of the French Academy of Sciences, and President of Seqens Scientific Committee: “Prof. Couvreur is a member of the French Academy of Sciences, of the National Academy of Medicine, and presided the National Academy of Pharmacy in 2020. He also holds prestigious positions in other foreign institutions, such as the National Academy of Engineering (USA) and the European Academy of Sciences.”

More than 600 articles have been published based on Professor Couvreur’s works, as well as 8 books, and 90 patents. With a strong entrepreneurial spirit, Professor Couvreur also founded three start-ups, and brought nanomedicine candidates in clinical trials.

“Seqens is extremely proud to welcome Professor Couvreur as a member of its Scientific Committee. We share the same values of entrepreneurship, and his outstanding scientific expertise and worldwide network, will boost our innovation capabilities.” says Pierre Luzeau, CEO of Seqens.

### **About SEQENS**

*SEQENS is a world leader in pharmaceutical synthesis and specialty ingredients.*

*With 24 production sites and 3 R&D centers in Europe, North America and Asia, SEQENS develops tailor-made solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and home care. Driven by a culture of excellence and a strong entrepreneurial spirit, our 3,200 employees are committed to providing our customers with the highest level of service and quality while acting ethically in accordance with our corporate social responsibility program.*

[press@seqens.com](mailto:press@seqens.com) / [www.seqens.com](http://www.seqens.com) / LinkedIn : SEQENS / Twitter : seqens\_group